Nucleic Acids Research, Vol 25, Issue 4 769-775, Copyright © 1997 by Oxford University Press
R Hormes, M Homann, I Oelze, P Marschall, M Tabler, F Eckstein and G Sczakiel
The length requirements of the antisense portion of hammerhead ribozymes
for efficacy in living cells was investigated. The HIV-1tat- directed
asymmetric hammerhead ribozyme alphaYRz195 was used with a 195 nt
3'-antisense arm and a 3 nt 5'-antisense portion as well as a set of
successively 3'-shortened derivatives thereof. In the 3'-antisense arm a
minimum length of 20 complementary nucleotides was required for efficient
association with a 645 nt target RNA transcript in vitro(for all constructs
kass ranged between 0.3 and 1.8x104/M/s). The cleavage rate constants
(kcleav) were independent of the length of the antisense flank and ranged
between 0.8 and 1.2x10-4/s. However, the length of the antisense arms, as
well as the mode of delivery and the subcellular location of the ribozymes,
had a dramatic effect on efficacy in HIV-1- producing human cells. When
proviral HIV-1 DNA and ribozymes were co- microinjected into the nucleus of
human cells, a minimum length of 51 nt in the antisense arm was necessary
for antisense- and ribozyme- mediated inhibition of HIV-1 replication.
Ribozymes with shorter antisense arms were almost ineffective. Conversely,
short chain ribozymes, including those with chemical modifications, were
superior to long chain ribozymes when co-microinjected into the cytoplasm.
When transfected, all ribozymes showed an antisense effect as well as an
additional ribozyme-mediated increase in inhibition. Consequences for the
design and application of ribozymes are discussed.
ARTICLES
The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells
Forschungsschwerpunkt Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. W. Rooney and K. L. Calame TIF1beta functions as a coactivator for C/EBPbeta and is required for induced differentiation in the myelomonocytic cell line U937 Genes & Dev., November 15, 2001; 15(22): 3023 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bramlage, E. Luzi, and F. Eckstein HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture Nucleic Acids Res., November 1, 2000; 28(21): 4059 - 4067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF]
|
|
|
|
|
|
H. A. James and I. Gibson The Therapeutic Potential of Ribozymes Blood, January 15, 1998; 91(2): 371 - 382. [Abstract] [Full Text] [PDF]
|
|